1Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis,2007,50(2) : 169 - 180.
2Zahran A, El- Husseini A, Shoker A. Can cystatin C replace creatinine to estimate glomerular filtration rate? A literature review. Am J Nephrol, 2007,27 (2) : 197 - 205.
3Mitsnefes MM, Kathman TS, Mishra J, et al. Serum neutrophil gelatinaseassociated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol, 2007,22 (1):101 - 108.
4Bolignano D, Coppolino G, Campo S, et al. Urinary neutrophil gelatinaseassociated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transplant, 2008,23(1) :414 - 416.
5Ravani P, Tripepi G, Malberti F, et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol,2005,16(8) :2449 - 2455.
6Kamijo A, Sugaya T, Hikawa A, et al. Urinary liver - type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem, 2006,284 ( 1 - 2) : 175 - 182.
7van Timrneren MM,van den Heuvel MC, Bailly V, et al. Tubular kidney injury molecule- 1 (KIM- 1) in human renal disease. J Pathol,2007,212(2) :209 - 217.
8Shi GP, Sukhova GK, Grubb A, et al. Cystatin C deficiency in human athercsclerosis and aortic aneurysms. J Clin Invest, 1999, 104(9) :1191 - 1197.
9Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinaseassociated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol, 2003,14 (10): 2534 - 2543.
10Mishra J,Dent C,Tarabishi R, et al. Neutrophil gelatinase- associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet, 2005,365 (9466) : 1231 - 1238.
2Akiba T, Tachib ana K, Togashi K, et al. Plasma human brain natriuretic peptide in chronic renal failure. Clin Nephrol, 1995, 44 Suppl 1:S61-S64.
3Safley DM, Awad A, Sullivan RA, et al. Changes in B-type natriuretic peptide levels in hemodialysis and the effect of depressed left ventricular function. Adv Chronic Kidney Dis,2005, 12:117-124.
4Foley RN, Parfrey PS, Samak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis, 1998, 32 (5 Suppl 3):Sl12-Sl19.
5Levin A, Djurdjev O,Barrett B, et al. Cardiovascular disease in patients with chronic kidney disease:geting to the heart of the matter. Am J Kidney Dis, 2001, 38:1398-1407.
6Mallamaci F, Zoccali C, Tripepi G, et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int, 2001, 59:1559-1566.
7Cataliotti A, Malatino LS, Jougasaki M, et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natfiuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc, 2001,76:1111-1119.
8Takami Y, Horio T, lwashima Y, et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in nondialysis-dependent CRF. Am J Kidney Dis, 2004, 44:420-428.
9Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis, 2005, 46:610-620.
10Nakatani T, Naganuma T, Masuda C, et al. Significance of brain natriuretic peptides in patients on continuous ambulatory peritoneal dialysis. Int J Mol Med, 2002, 10:457-461.
10Paweletz CP, Trock B, Pennanen M, et al. Petroicoin III. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: Potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers, 2001, 17(4):301-307.
